Chief Scientific Officer
Vetanco International, USA
Sherry Layton received her Ph.D. from the University of Arkansas where she studied poultry science. Her early career research in poultry immunology and molecular engineering set the foundation for her pioneering scientific successes in animal and public health. Over the last decade Dr. Layton developed and patented an innovative orally administered sub-unit vaccine platform, Biotech Vac. This research and development led to the recent introduction of Biotech Vac – Salmonella in Latin America, which provides poultry with immunological protection from all mobile Salmonella species, a first in the poultry industry, and will help reduce the risk of food-borne Salmonellosis in humans. Currently, she serves as CEO for Vetanco USA and Chief Scientific Officer for Vetanco International/BV Science, a global animal health and nutrition company where her research focuses on maintaining public and animal health; as well as ensuring food safety globally. Dr. Layton currently leads a research team of veterinarians and scientists in the U.S. and South America and has developed a pipeline of pioneering and effective vaccines. She is currently focused on supporting the introduction of Biotech Vac – Salmonella and Biotech Vac Coccidia in Latin America as well as establishing biologicals in the U.S. market with the newly formed Vetanco USA.
Poultry immunology and molecular engineering